✦ LIBER ✦

Fluorouracil, doxorubicin, cisplatin and altretamine in the treatment of metastatic carcinoma of unknown primary

✍ Scribed by Bécouarn, Y.; Brunet, R.; Barbé-Gaston, C.

Book ID: 122732502
Publisher: Elsevier Science
Year: 1989
Weight: 362 KB
Volume: 25
Category: Article
ISSN: 0277-5379
DOI: 10.1016/0277-5379(89)90133-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Epirubicin, cisplatin, and prolonged or

Epirubicin, cisplatin, and prolonged or brief infusional 5-fluorouracil in the treatment of carcinoma of unknown primary site

✍ C. S. Karapetis; D. Yip; K. Virik; A. Strickland; K. Ryder; M. Cowling; P. G. Ha 📂 Article 📅 2001 🏛 Springer US 🌐 English ⚖ 83 KB

5-fluorouracil, doxorubicin and mitomyci

5-fluorouracil, doxorubicin and mitomycin C (FAM) combination chemotherapy for metastatic adenocarcinoma of unknown primary

✍ van der Gaast, Ate; Verweij, Jaap; Planting, AndréS.Th.; Stoter, Gerrit 📂 Article 📅 1988 🏛 Elsevier Science ⚖ 350 KB

Infusional 5-fluorouracil and cisplatin

Infusional 5-fluorouracil and cisplatin as first-line chemotherapy in patients with carcinoma of unknown primary site

✍ Hitoshi Kusaba; Yoshihiro Shibata; Shuji Arita; Hiroshi Ariyama; Eishi Baba; Ken 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 64 KB

Phase II study of cisplatin, 5-fluoroura

Phase II study of cisplatin, 5-fluorouracil and folinic acid in patients with carcinoma of unknown primary origin

✍ Raber, Martin N.; Frost, Philip; Schmidt, Susan; Abbruzzese, James L.; Lenzi, Re 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 143 KB

Treatment and prognosis of metastatic ca

Treatment and prognosis of metastatic carcinoma of unknown primary: Analysis of 100 patients

✍ Alberts, A. S. ;Falkson, G. ;Falkson, H. C. ;van der Merwe, M. P. 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 387 KB

One hundred patients with metastatic carcinoma of unknown primary were analyzed to assess the importance of prognostic factors on survival. Patients were treated with cytostatic combinations, single drugs, or symptomatic care only. Response in the treatment groups ranged from 10% to 33%. The median

Metastatic carcinoma of the neck of unkn

Metastatic carcinoma of the neck of unknown primary origin

✍ Mario J. Acquarelli; Ronald S. Matsunaga; Kenneth Cruze 📂 Article 📅 1961 🏛 John Wiley and Sons 🌐 English ⚖ 515 KB